EP3977993A1 — Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
Assigned to Pfizer Inc · Expires 2022-04-06 · 4y expired
What this patent protects
The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such so…
USPTO Abstract
The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.
Drugs covered by this patent
- Vyndaqel (Tafamidis Meglumine) · Foldrx Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.